Efficacy of isobutylamido thiazolyl resorcinol for prevention of laser-induced post-inflammatory hyperpigmentation: A randomized, controlled trial

J Cosmet Dermatol. 2024 Jul;23(7):2450-2457. doi: 10.1111/jocd.16287. Epub 2024 Mar 18.

Abstract

Background: Q-switched (QS) Nd: YAG laser is one of the treatment options for solar lentigines (SLs). However, the incidence of post-inflammatory hyperpigmentation (PIH) is a common complication, especially in dark-complexioned skin. Isobutylamido thiazolyl resorcinol (ITR) has been reported as a preventive modality for ultraviolet B (UVB)-induced hyperpigmentation.

Aims: This study aims to evaluate the efficacy and safety of ITR for the prevention of laser-induced PIH.

Patients/methods: A randomized, evaluator-blinded study including 24 subjects with SLs was conducted. Three SLs of each patient were randomized into three groups, which were to apply ITR twice daily, once daily, and no application for 2 weeks. Thereafter, 532-nm QS Nd: YAG laser was performed. Incidence of laser-induced PIH, relative melanin index (RMI), mean luminance score (L*), hyperpigmentation score, and adverse events were recorded for 2 months post-laser.

Results: The incidence of PIH at the 4th week after laser treatment was significantly lower in the ITR twice-daily group compared to the no-application group (20.83% vs. 50%, p = 0.028). There was no statistically significant difference in RMI, mean L*, and hyperpigmentation score between treatments at all visits. No serious adverse events were reported regarding ITR application and laser treatment.

Conclusion: Two-week application of ITR prior to QS: Nd YAG laser treatment may potentially reduce the incidence of PIH. A longer duration of application, including after the laser procedure, may be more beneficial for the prevention of laser-induced PIH.

Keywords: aged spot; hydroquinone; hyperpigmentation; laser; resorcinol.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Female
  • Humans
  • Hyperpigmentation* / etiology
  • Hyperpigmentation* / prevention & control
  • Lasers, Solid-State* / therapeutic use
  • Lentigo* / etiology
  • Lentigo* / prevention & control
  • Lentigo* / therapy
  • Male
  • Middle Aged
  • Resorcinols* / administration & dosage
  • Resorcinols* / adverse effects
  • Resorcinols* / therapeutic use
  • Single-Blind Method
  • Treatment Outcome

Substances

  • Resorcinols